Changes of Biochemical Bone Markers and Bone Mineral Density after Hormone Replacement Therapy in Korean Women.
- Author:
Kyong Soo PARK
1
;
Do Joon PARK
;
Seong Yeon KIM
;
Bo Youn CHO
;
Hong Kyu LEE
;
Jae Hyeon KIM
;
Jeong Goo KIM
Author Information
1. Department of Internal Medicine, The Institute of Endocrinology, Natrtion and Metabolism.
- Publication Type:Original Article
- Keywords:
Hormone replacement therapy;
Biochemical bone marker;
Bone mineral density;
Early menopause
- MeSH:
Alkaline Phosphatase;
Bone Density*;
Bone Resorption;
Collagen Type I;
Estrogens;
Female;
Femur;
Femur Neck;
Hormone Replacement Therapy*;
Humans;
Medroxyprogesterone;
Menopause;
Osteocalcin;
Osteogenesis;
Spine
- From:Journal of Korean Society of Endocrinology
2000;15(2):226-236
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Biochemical bone markers have been suggested to reflect postmenopausal high bone turnover. These markers could be useful in following response to hormone replacement therapy (HRT). But we have few studies about the sequential changes of biochemical bone markers and bone mass after HRT in Korean women, and it is unclear whether women with early menopause have different response to HRT from women with normal menopause. The aims of the present study were to see the sequential changes of biochemical bone markers and bone mass after HRT in Korean women, to examine whether a single baseline biochemical bone marker or a change in biochemical bone marker could predict subsequent bone mass, and to determine the difference of response to HRT between women with early menopause and women with normal menopause. METHODS: Postmenopausal women (n=21) were divided with into three groups according to their age at menopause (AAM): the first group with AAM < or = 43 years (early menopause group, n=7), the second group with 43 years < or = AAM < or = 50 years (n=4), and the third group with AAM > or = 50 years (normal menopause group, n=10). For the HRT, conjugated estrogen (0.625mg per day) and continuous or cyclic medroxyprogesterone (2.5-10mg per day) were administered. Bone mineral density (BMD) was measured at baseline and 12 months and biochemical bone markers were measured at baseline and 3, 6, and 12 months during HRT. RESULTS: Deoxypyridinoline, type 1 collagen N-telopeptide, bone alkaline phosphatase, and osteocalcin were significantly decreased at 3 months, and mean percent changes from baseline of bone resorption markers were larger than those of bone formation markers. At 12 months, BMD was significantly increased at lumbar spine and Ward's triangle. But BMD was not significantly increased at femur neck and femur trochanter. Two baseline bone markers (bone alkaline phosphatase and type 1 collagen N-telopeptide) correlated with changes of BMD but any changes of bone markers at 3, 6 months didn't correlate with changes of BMD. In early menopause group, changes of bone markers and BMD were larger than those in normal menopause group, but the difference between the two groups was not significant. CONCLUSION: All four bone markers showed significant reduction at 3 months, but bone resorption markers were decreased more markedly and rapidly, and some baseline bone markers can predict the change of BMD after HRT. The difference of response to HRT between early menopause group and normal menopause group was not significant.
